<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157651</url>
  </required_header>
  <id_info>
    <org_study_id>MCT-15226</org_study_id>
    <nct_id>NCT00157651</nct_id>
  </id_info>
  <brief_title>Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters</brief_title>
  <official_title>A Double-Blind, Placebo Controlled, Randomized Trial of Low-Intensity Adjusted-Dose Warfarin for the Prevention of Mechanical Malfunction of Double-Lumen Haemodialysis Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines whether low intensity, dose adjusted warfarin prolongs the time to
      mechanical failure of hemodialysis catheters without resulting in an unacceptable rate of
      bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with end-stage renal disease receiving or about to initiate hemodialysis are
      randomized to receive either adjusted dose warfarin to achieve an INR of 1.5-1.9 or adjusted
      dose placebo within 72 hours of hemodialysis catheter placement. The primary outcome is
      mechanical failure of the catheter, as outlined below.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from catheter insertion to mechanical failure. This is defined as inability to aspirate or persistent blood flow less than 200mL/min after line reversal, patient repositioning and rotational manipulation of the catheter.</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood flow rate and adequacy of dialysis.</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding events.</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause.</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Thrombosis</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receiving matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor</description>
    <arm_group_label>2</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly placed double-lumen hemodialysis catheter

        Exclusion Criteria:

          -  Major bleed within last 3 months

          -  Platelet count less than 50 x 10 9/L or current coagulopathy (most recent INR &gt; 1.5,
             not due to warfarin)

          -  Active peptic ulcer disease

          -  Anticipated need for invasive intervention within next 2 weeks

          -  Taking warfarin for an indication other than access prophylaxis

          -  Allergic to, or intolerant of, warfarin

          -  Pregnant

          -  Woman of child-bearing age who has not agreed to use an adequate method of birth
             control for the duration of the study

          -  Catheter likely needed for 2 weeks or less

          -  Patient previously took part in the study

          -  Patient has known aortic aneurysm of 6cm or greater

          -  Patients nephrologist has refused consent

          -  Patient has refused consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alistair J Ingram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine M Clase, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alistair Ingram Professor of Medicine</name_title>
    <organization>McMaster University</organization>
  </responsible_party>
  <keyword>end stage renal disease</keyword>
  <keyword>thrombosis</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 31, 2017</submitted>
    <returned>March 20, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

